Analysts have been eager to weigh in on the Healthcare sector with new ratings on Amneal Pharmaceuticals (AMRX – Research Report) and Community Health (CYH – Research Report).
Amneal Pharmaceuticals (AMRX)
In a report released today, Balaji Prasad from Barclays reiterated a Buy rating on Amneal Pharmaceuticals, with a price target of $8.00. The company’s shares closed last Wednesday at $6.05, close to its 52-week high of $6.46.
According to TipRanks.com, Prasad is a 2-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Amneal Pharmaceuticals with a $7.42 average price target.
See the top stocks recommended by analysts >>
Community Health (CYH)
In a report released today, Andrew Mok CFA from Barclays maintained a Hold rating on Community Health, with a price target of $3.00. The company’s shares closed last Wednesday at $3.03.
According to TipRanks.com, CFA is a 1-star analyst with an average return of
Community Health has an analyst consensus of Moderate Buy, with a price target consensus of $4.45.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on AMRX:
- Bausch Health (NYSE:BHC) Falls 7% amid New Legal Issues
- Bausch suit creates added uncertainty on B+L spin, says TD Cowen
- Bausch Health files patent lawsuit against Amneal Pharmaceuticals
- Amneal receives FDA approval for ciprofloxacin, dexamethasone otic suspension
- Amneal Pharmaceuticals price target raised to $8 from $6 at Piper Sandler
